Blood Test Predicts How Diseases Will Progress — Before Symptoms Worsen

Scientists at Imperial College London have developed a blood test that reads the future. By analysing RNA markers — molecular signatures left when genes switch on and off during illness — the test can predict how a disease will progress and, crucially, how a patient will respond to treatment.

In proof-of-concept studies, the test successfully predicted outcomes for infectious and chronic diseases. Most impressively, it forecast how inflammatory bowel disease patients would respond to specific therapies — potentially sparing patients months of trial-and-error treatment.

"The patterns of gene expression we see in the blood offer clues as to what is happening… not just where someone is right now, but where they are going to be in the next few hours or days," said Dr Clair Duncan of Imperial.

A working clinical version could be available within five years.

Key Facts & Figures - Mechanism: RNA marker analysis in blood - Applications: infectious disease, chronic disease, treatment response - Proof-of-concept: successfully predicted IBD therapy response - Timeline to clinical use: potentially 5 years - Institution: Imperial College London - Source: Nature Communications, Positive.News

Context & Background Predictive diagnostics represent a shift from reactive to proactive medicine. Rather than waiting for symptoms to worsen before adjusting treatment, doctors could use biomarker signatures to make personalised decisions earlier. This builds on growing interest in transcriptomics and liquid biopsy technologies.

Limitations & Caveats - Currently proof-of-concept only - Five-year timeline is optimistic - Cost and NHS integration unknown - RNA analysis requires specialised lab infrastructure - Needs validation across larger, more diverse patient populations

---